<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577993</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-261</org_study_id>
    <secondary_id>NCI-2010-01566</secondary_id>
    <nct_id>NCT00577993</nct_id>
  </id_info>
  <brief_title>Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients</brief_title>
  <official_title>Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare chemotherapy given with rituximab to&#xD;
      chemotherapy followed by rituximab. The safety of both treatment schedules will be studied.&#xD;
      Laboratory tests of genetic changes in blood and bone marrow before and during the study will&#xD;
      also be monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rituximab is a monoclonal antibody that is designed to attach to leukemia cells and activate&#xD;
      a series of events that may cause the cancer cells to die.&#xD;
&#xD;
      Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic&#xD;
      material of cells). This may increase the likelihood of the cells dying.&#xD;
&#xD;
      Mitoxantrone is designed to stop cancer cells from making DNA, which may stop the cells from&#xD;
      making more cells.&#xD;
&#xD;
      Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body.&#xD;
      Dexamethasone is often given to MM patients in combination with other chemotherapy to treat&#xD;
      cancer.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found eligible to take part in this study, you will be randomly assigned (as in&#xD;
      the flip of a coin) to 1 of 2 study groups. Each group will receive 8 &quot;cycles&quot; of treatment.&#xD;
      One (1) cycle will last 28 days.&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
      If you are in Group 1, you will receive the following drugs at the following times. Each&#xD;
      study cycle is 28 days:&#xD;
&#xD;
        -  Rituximab will be given through a needle in the vein over about 90 minutes on Days 1 and&#xD;
           8 of the first course Cycle 1, and on Day 1 only of Cycles 2-5 of Fludarabine/&#xD;
           Mitoxantrone/ Dexamethasone (FND) treatment.&#xD;
&#xD;
        -  Fludarabine will be given through a needle in the vein over about 15 minutes on Days 2-4&#xD;
           of each cycle.&#xD;
&#xD;
        -  Mitoxantrone will be given through a needle in the vein over about 15 minutes on Day 2&#xD;
           of each cycle.&#xD;
&#xD;
        -  You will take dexamethasone by mouth with water on Days 1-5 of each 28-day cycle (FND).&#xD;
&#xD;
      If you miss any doses of the study drugs, please contact the research staff for instructions.&#xD;
&#xD;
      You will not receive rituximab in Cycles 6-8. When the 8 cycles are finished, you will begin&#xD;
      receiving the drug interferon on Days 1-14 each month for 1 year. Dexamethasone will be given&#xD;
      on Days 1-3 every month for 1 year.&#xD;
&#xD;
      Patients in group 2 will receive fludarabine on Days 1-3, mitoxantrone on Day 1, and&#xD;
      dexamethasone on Days 1-5 of each 28-day cycle. When 8 cycles of treatment are finished,&#xD;
      patients will begin receiving the drug interferon on Days 1-14 each month for 1 year.&#xD;
      Dexamethasone will be given on Days 1-3 every month for 1 year. About 4 months after&#xD;
      interferon treatment starts, patients in group 2 will begin receiving rituximab once a month&#xD;
      for 6 months.&#xD;
&#xD;
      Other drugs may be given to help decrease the risk of or ease side effects. Treatment may be&#xD;
      delayed or stopped if side effects are severe.&#xD;
&#xD;
      Most of the drugs are given by vein. A catheter (a tube) will be placed in a vein to decrease&#xD;
      the number of needle sticks. Dexamethasone may be taken by mouth instead of given by vein.&#xD;
&#xD;
      Some patients in this study, with changes in certain genes will receive different&#xD;
      chemotherapy drugs than other patients in the study will. The patients will, like all the&#xD;
      other patients, receive rituximab and interferon. But instead of the FND chemotherapy&#xD;
      regimen, they will receive a sequence of three regimens, CHOD-Bleo, ESHAP, and NOPP. The&#xD;
      drugs in these regimens include: cyclophosphamide, doxorubicin, vincristine, bleomycin,&#xD;
      VP-16, Ara-C, cisplatin, mitoxantrone, procarbazine, and corticosteroids (prednisone,&#xD;
      methylprednisolone, dexamethasone).&#xD;
&#xD;
      During the study, patients will have blood tests every week. Complete exams will be given in&#xD;
      Cycles 2 and 4; patients will return to the clinic for these. Every 2 or 3 cycles, patients&#xD;
      will have a chest x-ray and CT scans of the abdomen and pelvis. Bone marrow samples will be&#xD;
      taken. Heart function tests (EKG) will be done as needed.&#xD;
&#xD;
      After the study ends, patients will return for checkups every 3 months in the first year,&#xD;
      every 4 months in years 2 and 3, and every 6 months in years 4 and 5. After that, checkups&#xD;
      will be needed once a year. Blood and bone marrow samples will be taken at these visits.&#xD;
&#xD;
      This is an investigational study. Rituximab is approved by FDA for commercial use. The other&#xD;
      drugs used in the study are also approved for commercial use. About 210 patients will take&#xD;
      part in the study. All will be enrolled at University of Texas MD Anderson Cancer Center&#xD;
      (UTMDACC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 1998</start_date>
  <completion_date type="Actual">August 24, 2017</completion_date>
  <primary_completion_date type="Actual">August 24, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Survival (10 Years) by Treatment</measure>
    <time_frame>10 Years</time_frame>
    <description>Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression Free Survival (10 Years) by Treatment</measure>
    <time_frame>10 years</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine/Novantrone/Decadron Followed by Interferon &amp; Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.</description>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <other_name>2-fluoro-Ara Amp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novantrone</intervention_name>
    <description>Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.</description>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
    <other_name>Mitoxantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decadron</intervention_name>
    <description>Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.</description>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.</description>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>Anti-CD20</other_name>
    <other_name>IDEC-C2B8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon</intervention_name>
    <description>Group 1 = After Completion of Fludarabine, Novantrone, &amp; Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine &amp; Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.</description>
    <arm_group_label>1: FND + Rituximab Followed by Interferon</arm_group_label>
    <arm_group_label>2: FND Followed by Interferon &amp; Rituximab</arm_group_label>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
    <other_name>Interferon Alpha-2b</other_name>
    <other_name>IFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>25 mg/m^2 IV Days 2 &amp; 3 of 1st Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>.7 mg/m^2 IV Days 2 &amp; 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>5 unit/m^2 IV Days 2 &amp; 3 of 1st Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m^2 IV Day 2 of 1st Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m^2 IV Days 1 through 4 of 2nd Sequence</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>1.5 gm/m^2 IV Day 5 of 2nd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl-Prednisolone</intervention_name>
    <description>500 mg IV Days 1 through 5 of 2nd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine</intervention_name>
    <description>100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100 mg PO Days 1 through 5 of 3rd Sequence.</description>
    <arm_group_label>3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001:&#xD;
             eligibility restricted to follicular lymphoma]&#xD;
&#xD;
          2. Age &lt;76&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <results_first_submitted>April 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Novantrone</keyword>
  <keyword>Mitoxantrone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Anti-CD20</keyword>
  <keyword>IDEC-C2B8</keyword>
  <keyword>Chimeric Anti-CD20 Antibody</keyword>
  <keyword>Interferon</keyword>
  <keyword>Interferon Alpha-2b</keyword>
  <keyword>IFN</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Methyl-Prednisolone</keyword>
  <keyword>Procarbazine</keyword>
  <keyword>Prednisone</keyword>
  <keyword>FND</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2001</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT00577993/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: March 1998 to May 2002</recruitment_details>
      <pre_assignment_details>35 participants without Bcl Gene rearrangement were not randomized to the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex</description>
        </group>
        <group group_id="P2">
          <title>Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex.</description>
        </group>
        <group group_id="P3">
          <title>Patients Without Bcl Gene Rearrangement</title>
          <description>ATT9 cycles; Rituximab 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Conversion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uninsured</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No data collected for Patients w/o bcl gene for rearrangement for the Study Specific Measure Indolent Lymphoma Subtype</population>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex</description>
        </group>
        <group group_id="B2">
          <title>Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex.</description>
        </group>
        <group group_id="B3">
          <title>Patients w/o Bcl Gene Rearrangement</title>
          <description>ATT 9 cycles; Rituximab 6 cycles</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="23" upper_limit="76"/>
                    <measurement group_id="B2" value="54" lower_limit="19" upper_limit="75"/>
                    <measurement group_id="B3" value="51" lower_limit="33" upper_limit="70"/>
                    <measurement group_id="B4" value="52" lower_limit="19" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Arab Emirates</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="35"/>
                    <count group_id="B4" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indolent Lymphoma Subtype</title>
          <description>Indolent lymphomas characterized by slow-growing B-cell malignancies: Small lymphocyte (SLL), Malignant Zone (MZL), &amp; Follicular Lymphoma (FL).</description>
          <population>No data collected for Patients w/o bcl gene for rearrangement for the Study Specific Measure Indolent Lymphoma Subtype</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>FL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MZL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Survival (10 Years) by Treatment</title>
        <description>Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.</description>
        <time_frame>10 Years</time_frame>
        <population>The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab</title>
            <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex</description>
          </group>
          <group group_id="O2">
            <title>Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</title>
            <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival (10 Years) by Treatment</title>
          <description>Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.</description>
          <population>The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression Free Survival (10 Years) by Treatment</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>10 years</time_frame>
        <population>The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab</title>
            <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex</description>
          </group>
          <group group_id="O2">
            <title>Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</title>
            <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression Free Survival (10 Years) by Treatment</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years</time_frame>
      <desc>Adverse events reported for the 2 randomized arms and not for the participants without bcl gene rearrangement.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex</description>
        </group>
        <group group_id="E2">
          <title>Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)</title>
          <description>Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea/Emesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea / Emisis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Rash / Pruitius</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nathan Fowler,MD, Clinical Professor, Lymphoma-Myeloma</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(832) 671-3018</phone>
      <email>nfowler@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

